Literature DB >> 8412017

Canavan disease: biochemical and molecular studies.

R Matalon1, R Kaul, K Michals.   

Abstract

Deficiency of the enzyme aspartoacylase and the accumulation of N-acetylaspartic acid lead to a severe leukodystrophy and spongy degeneration of the brain, Canavan disease (McKusick 271900). Since our discovery in 1988 of the defect in Canavan disease, 144 patients with Canavan disease have been diagnosed in our laboratory. Most of these children are of Ashkenazi Jewish extraction. The level of enzyme activity can be used for carrier testing. Prenatal diagnosis has been difficult using the enzyme assay owing to the low activity of aspartoacylase in cultured chorionic villus samples or amniocytes. The determination of N-acetylaspartic acid in the amniotic fluid is another parameter for diagnosis; however, the levels may not always be elevated. Bovine and human aspartoacylase have been purified in our laboratory. Bovine and human cDNA and genomic clones have been isolated and six exons have been localized. This information is being used for the study of Canavan disease at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412017     DOI: 10.1007/bf00711906

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  30 in total

1.  SPONGY DEGENERATION OF THE NERVOUS SYSTEM. A REPORT OF FOUR CASES WITH A REVIEW OF THE LITERATURE.

Authors:  D S BUCHANAN; R L DAVIS
Journal:  Neurology       Date:  1965-03       Impact factor: 9.910

2.  Studies on the function of N-acetyl aspartic acid in brain.

Authors:  J C McIntosh; J R Cooper
Journal:  J Neurochem       Date:  1965 Sep-Oct       Impact factor: 5.372

3.  Familial spongy degeneration of the central nervous system (Van Bogaert-Bertrand disease). An ultrastructural study.

Authors:  P Gambetti; W J Mellman; N K Gonatas
Journal:  Acta Neuropathol       Date:  1969-01-31       Impact factor: 17.088

4.  Amino acid sequence of the N alpha-terminal 201 residues of human erythrocyte membrane band 3.

Authors:  R K Kaul; S N Murthy; A G Reddy; T L Steck; H Kohler
Journal:  J Biol Chem       Date:  1983-07-10       Impact factor: 5.157

Review 5.  N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain.

Authors:  D L Birken; W H Oldendorf
Journal:  Neurosci Biobehav Rev       Date:  1989       Impact factor: 8.989

6.  Spongy degeneration of the neuraxis (Canavan-van Bogaert disease) and N-acetylaspartic aciduria.

Authors:  B Echenne; P Divry; C Vianey-Liaud
Journal:  Neuropediatrics       Date:  1989-05       Impact factor: 1.947

7.  Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.

Authors:  R Matalon; K Michals; D Sebesta; M Deanching; P Gashkoff; J Casanova
Journal:  Am J Med Genet       Date:  1988-02

8.  Computed tomography in the diagnosis of Canavan's disease.

Authors:  A R Rushton; B A Shaywitz; C C Duncan; R B Geehr; E E Manuelidis
Journal:  Ann Neurol       Date:  1981-07       Impact factor: 10.422

9.  Immunohistochemical localization of N-acetylaspartate in rat brain.

Authors:  J R Moffett; M A Namboodiri; C B Cangro; J H Neale
Journal:  Neuroreport       Date:  1991-03       Impact factor: 1.837

10.  In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan's disease) by proton spectroscopy.

Authors:  W Grodd; I Krägeloh-Mann; D Petersen; F K Trefz; K Harzer
Journal:  Lancet       Date:  1990-08-18       Impact factor: 79.321

View more
  13 in total

1.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

2.  Prenatal diagnosis for Canavan disease: the use of DNA markers.

Authors:  R Matalon; R Kaul; G P Gao; K Michals; R G Gray; S Bennett-Briton; A Norman; M Smith; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Unreliable verification of prenatal diagnosis of Canavan disease: aspartoacylase activity in deficient and normal fetal skin fibroblasts.

Authors:  M O Rolland; G Mandon; A Bernard; M T Zabot; M Mathieu
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

4.  Detection of increased urinary N-acetylaspartylglutamate in Canavan disease.

Authors:  A P Burlina; A Corazza; V Ferrari; P Erhard; B Künnecke; J Seelig; A B Burlina
Journal:  Eur J Pediatr       Date:  1994-07       Impact factor: 3.183

5.  Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.

Authors:  C George Priya Doss; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2017-09-06       Impact factor: 3.584

Review 6.  Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.

Authors:  M H Baslow; T R Resnik
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

7.  Canavan disease: mutations among Jewish and non-Jewish patients.

Authors:  R Kaul; G P Gao; M Aloya; K Balamurugan; A Petrosky; K Michals; R Matalon
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

8.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

9.  Structural modeling of p.V31F variant in the aspartoacylase gene.

Authors:  Navaneethakrishnan Krishnamoorthy; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2016-01-21       Impact factor: 3.584

10.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.